# A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)

> **NCT00683930** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 96 (actual)

## Conditions studied

- Pemphigus Vulgaris (PV)

## Interventions

- **DRUG:** Mycophenolate Mofetil 2 g/Day
- **DRUG:** Mycophenolate Mofetil (MMF) 3 g/Day
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00683930
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2011-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00683930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00683930, "A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00683930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*